Yuyu Pharma Inc Asset Resilience Ratio
Yuyu Pharma Inc asset resilience ratio. Yuyu Pharma Inc (000225) has an Asset Resilience Ratio of 3.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 000225 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Yuyu Pharma Inc (2014–2025)
Asset resilience ratio of Yuyu Pharma Inc from 2014 to 2025. This chart shows how Yuyu Pharma Inc's Asset Resilience Ratio has changed over time. See 000225 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Yuyu Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Yuyu Pharma Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩6.88 Billion | 3.31% |
| Total Liquid Assets | ₩6.88 Billion | 3.31% |
Asset Resilience Insights
- Limited Liquidity: Yuyu Pharma Inc maintains only 3.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yuyu Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Yuyu Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
Yuyu Pharma Inc Asset Resilience Ratio by Year (2014–2025)
Yuyu Pharma Inc asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Yuyu Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.74% | ₩3.61 Billion ≈ $2.45 Million |
₩207.22 Billion ≈ $140.43 Million |
+1.35pp |
| 2024-12-31 | 0.39% | ₩817.27 Million ≈ $553.85K |
₩207.69 Billion ≈ $140.75 Million |
-0.49pp |
| 2023-12-31 | 0.88% | ₩1.75 Billion ≈ $1.19 Million |
₩198.21 Billion ≈ $134.33 Million |
-1.65pp |
| 2022-12-31 | 2.53% | ₩4.94 Billion ≈ $3.35 Million |
₩195.21 Billion ≈ $132.29 Million |
+2.41pp |
| 2020-12-31 | 0.12% | ₩180.00 Million ≈ $121.98K |
₩154.90 Billion ≈ $104.97 Million |
-0.29pp |
| 2018-12-31 | 0.40% | ₩545.95 Million ≈ $369.98K |
₩135.23 Billion ≈ $91.64 Million |
-0.01pp |
| 2017-12-31 | 0.41% | ₩500.00 Million ≈ $338.84K |
₩121.49 Billion ≈ $82.33 Million |
-0.05pp |
| 2016-12-31 | 0.46% | ₩509.59 Million ≈ $345.34K |
₩111.30 Billion ≈ $75.43 Million |
-0.02pp |
| 2015-12-31 | 0.48% | ₩500.00 Million ≈ $338.84K |
₩104.33 Billion ≈ $70.70 Million |
-0.06pp |
| 2014-12-31 | 0.54% | ₩550.00 Million ≈ $372.73K |
₩101.40 Billion ≈ $68.72 Million |
-- |
About Yuyu Pharma Inc
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc.… Read more